Pharmacy Medical News about Neuroblastoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Expert Opinion on Investigational Drugs, 10/09/09

Oehme I et al. – HDAC8 expression correlates with poor outcome in neuroblastoma and selective HDAC8 inhibition induces differentiation. In contrast, the targeting of other HDAC family members results in a completely different phenotype. Because HDAC8–selective inhibitors are available, HDAC8 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.

<< Previous
Colistin and polymyxin B: A re-emergence

Next >>
Pharmacotherapy of Addictive Disorders

Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q
Oncogene, 11/12/09 Relevance Score: 89%

Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma
American Journal of Surgical Pathology, 10/28/09 Relevance Score: 88%

Interferon-gamma–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo
Clinical Cancer Research, 10/19/09 Relevance Score: 88%

Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy
Pediatric Radiology, 10/05/09 Relevance Score: 88%

Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells
Molecular Cancer, 10/02/09 Relevance Score: 88%